Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 29

1.

Evidence of a chemopreventive effect of progestin unrelated to ovulation on reproductive tract cancers in the egg-laying hen.

Rodriguez GC, Barnes HJ, Anderson KE, Whitaker RS, Berchuck A, Petitte JN, Lancaster JM, Wenham RM, Turbov JM, Day R, Maxwell GL, Carver DK.

Cancer Prev Res (Phila). 2013 Dec;6(12):1283-92. doi: 10.1158/1940-6207.CAPR-12-0426. Epub 2013 Oct 17.

2.

Quantitative detection of RASSF1A DNA promoter methylation in tumors and serum of patients with serous epithelial ovarian cancer.

Bondurant AE, Huang Z, Whitaker RS, Simel LR, Berchuck A, Murphy SK.

Gynecol Oncol. 2011 Dec;123(3):581-7. doi: 10.1016/j.ygyno.2011.08.029. Epub 2011 Sep 28.

PMID:
21955482
3.

Ovarian cancer tumor infiltrating T-regulatory (T(reg)) cells are associated with a metastatic phenotype.

Barnett JC, Bean SM, Whitaker RS, Kondoh E, Baba T, Fujii S, Marks JR, Dressman HK, Murphy SK, Berchuck A.

Gynecol Oncol. 2010 Mar;116(3):556-62. doi: 10.1016/j.ygyno.2009.11.020. Epub 2009 Dec 14.

PMID:
20006900
4.

Targeting slow-proliferating ovarian cancer cells.

Kondoh E, Mori S, Yamaguchi K, Baba T, Matsumura N, Cory Barnett J, Whitaker RS, Konishi I, Fujii S, Berchuck A, Murphy SK.

Int J Cancer. 2010 May 15;126(10):2448-56. doi: 10.1002/ijc.24919.

5.

Elevated MAL expression is accompanied by promoter hypomethylation and platinum resistance in epithelial ovarian cancer.

Lee PS, Teaberry VS, Bland AE, Huang Z, Whitaker RS, Baba T, Fujii S, Secord AA, Berchuck A, Murphy SK.

Int J Cancer. 2010 Mar 15;126(6):1378-89. doi: 10.1002/ijc.24797.

6.

Yin yang 1 modulates taxane response in epithelial ovarian cancer.

Matsumura N, Huang Z, Baba T, Lee PS, Barnett JC, Mori S, Chang JT, Kuo WL, Gusberg AH, Whitaker RS, Gray JW, Fujii S, Berchuck A, Murphy SK.

Mol Cancer Res. 2009 Feb;7(2):210-20. doi: 10.1158/1541-7786.MCR-08-0255. Epub 2009 Feb 10.

7.

Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells.

Baba T, Convery PA, Matsumura N, Whitaker RS, Kondoh E, Perry T, Huang Z, Bentley RC, Mori S, Fujii S, Marks JR, Berchuck A, Murphy SK.

Oncogene. 2009 Jan 15;28(2):209-18. doi: 10.1038/onc.2008.374. Epub 2008 Oct 6.

PMID:
18836486
8.

An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer.

Dressman HK, Berchuck A, Chan G, Zhai J, Bild A, Sayer R, Cragun J, Clarke J, Whitaker RS, Li L, Gray J, Marks J, Ginsburg GS, Potti A, West M, Nevins JR, Lancaster JM.

J Clin Oncol. 2007 Feb 10;25(5):517-25. Retraction in: J Clin Oncol. 2012 Feb 20;30(6):678.

PMID:
17290060
9.

Regulation of the metastasis suppressor gene MKK4 in ovarian cancer.

Spillman MA, Lacy J, Murphy SK, Whitaker RS, Grace L, Teaberry V, Marks JR, Berchuck A.

Gynecol Oncol. 2007 May;105(2):312-20. Epub 2007 Feb 5.

10.

Identification of genes associated with ovarian cancer metastasis using microarray expression analysis.

Lancaster JM, Dressman HK, Clarke JP, Sayer RA, Martino MA, Cragun JM, Henriott AH, Gray J, Sutphen R, Elahi A, Whitaker RS, West M, Marks JR, Nevins JR, Berchuck A.

Int J Gynecol Cancer. 2006 Sep-Oct;16(5):1733-45.

PMID:
17009964
11.

Frequent IGF2/H19 domain epigenetic alterations and elevated IGF2 expression in epithelial ovarian cancer.

Murphy SK, Huang Z, Wen Y, Spillman MA, Whitaker RS, Simel LR, Nichols TD, Marks JR, Berchuck A.

Mol Cancer Res. 2006 Apr;4(4):283-92.

12.

Gene expression patterns that characterize advanced stage serous ovarian cancers.

Lancaster JM, Dressman HK, Whitaker RS, Havrilesky L, Gray J, Marks JR, Nevins JR, Berchuck A.

J Soc Gynecol Investig. 2004 Jan;11(1):51-9.

PMID:
14706684
13.

Progestin-induced apoptosis in the Macaque ovarian epithelium: differential regulation of transforming growth factor-beta.

Rodriguez GC, Nagarsheth NP, Lee KL, Bentley RC, Walmer DK, Cline M, Whitaker RS, Isner P, Berchuck A, Dodge RK, Hughes CL.

J Natl Cancer Inst. 2002 Jan 2;94(1):50-60.

PMID:
11773282
14.

Loss of expression of the p16 tumor suppressor gene is more frequent in advanced ovarian cancers lacking p53 mutations.

Havrilesky LJ, Alvarez AA, Whitaker RS, Marks JR, Berchuck A.

Gynecol Oncol. 2001 Dec;83(3):491-500.

PMID:
11733961
15.

Thrombospondin-1 expression in epithelial ovarian carcinoma: association with p53 status, tumor angiogenesis, and survival in platinum-treated patients.

Alvarez AA, Axelrod JR, Whitaker RS, Isner PD, Bentley RC, Dodge RK, Rodriguez GC.

Gynecol Oncol. 2001 Aug;82(2):273-8.

PMID:
11531279
16.

The prognostic significance of angiogenesis in epithelial ovarian carcinoma.

Alvarez AA, Krigman HR, Whitaker RS, Dodge RK, Rodriguez GC.

Clin Cancer Res. 1999 Mar;5(3):587-91.

17.

Mucin gene expression in ovarian cancers.

Giuntoli RL 2nd, Rodriguez GC, Whitaker RS, Dodge R, Voynow JA.

Cancer Res. 1998 Dec 1;58(23):5546-50.

18.

Effect of progestin on the ovarian epithelium of macaques: cancer prevention through apoptosis?

Rodriguez GC, Walmer DK, Cline M, Krigman H, Lessey BA, Whitaker RS, Dodge R, Hughes CL.

J Soc Gynecol Investig. 1998 Sep-Oct;5(5):271-6.

PMID:
9773403
19.

Suppression of diacylglycerol levels by antibodies reactive with the c-erbB-2 (HER-2/neu) gene product p185c-erbB-2 in breast and ovarian cancer cell lines.

Boente MP, Berchuck A, Whitaker RS, Kalén A, Xu FJ, Clarke-Pearson DL, Bell RM, Bast RC Jr.

Gynecol Oncol. 1998 Jul;70(1):49-55.

PMID:
9698473
20.

Chemotherapy-induced apoptosis in epithelial ovarian cancers.

Havrilesky LJ, Elbendary A, Hurteau JA, Whitaker RS, Rodriguez GC, Berchuck A.

Obstet Gynecol. 1995 Jun;85(6):1007-10.

PMID:
7770245
21.

Regulation of apoptosis in normal and malignant ovarian epithelial cells by transforming growth factor beta.

Havrilesky LJ, Hurteau JA, Whitaker RS, Elbendary A, Wu S, Rodriguez GC, Bast RC Jr, Berchuck A.

Cancer Res. 1995 Feb 15;55(4):944-8.

22.

Transforming growth factor-beta inhibits proliferation of human ovarian cancer cells obtained from ascites.

Hurteau J, Rodriguez GC, Whitaker RS, Shah S, Mills G, Bast RC, Berchuck A.

Cancer. 1994 Jul 1;74(1):93-9.

23.

Overexpression of the tyrosine phosphatase PTP1B is associated with human ovarian carcinomas.

Wiener JR, Hurteau JA, Kerns BJ, Whitaker RS, Conaway MR, Berchuck A, Bast RC Jr.

Am J Obstet Gynecol. 1994 Apr;170(4):1177-83.

PMID:
8166206
24.

Serum levels of HER-2 neu (C-erbB-2) correlate with overexpression of p185neu in human ovarian cancer.

McKenzie SJ, DeSombre KA, Bast BS, Hollis DR, Whitaker RS, Berchuck A, Boyer CM, Bast RC Jr.

Cancer. 1993 Jun 15;71(12):3942-6.

25.
26.

Antibody-induced growth inhibition is mediated through immunochemically and functionally distinct epitopes on the extracellular domain of the c-erbB-2 (HER-2/neu) gene product p185.

Xu F, Lupu R, Rodriguez GC, Whitaker RS, Boente MP, Berchuck A, Yu Y, DeSombre KA, Boyer CM, Bast RC Jr.

Int J Cancer. 1993 Feb 1;53(3):401-8.

PMID:
7679090
27.

Growth regulation and transformation of ovarian epithelium.

Berchuck A, Kohler MF, Boente MP, Rodriguez GC, Whitaker RS, Bast RC Jr.

Cancer. 1993 Jan 15;71(2 Suppl):545-51. Review.

28.

The effect of antibodies and immunotoxins reactive with HER-2/neu on growth of ovarian and breast cancer cell lines.

Rodríguez GC, Boente MP, Berchuck A, Whitaker RS, O'Briant KC, Xu F, Bast RC Jr.

Am J Obstet Gynecol. 1993 Jan;168(1 Pt 1):228-32.

PMID:
8420332
29.

Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer. II. Relationship between receptor expression and response to epidermal growth factor.

Rodriguez GC, Berchuck A, Whitaker RS, Schlossman D, Clarke-Pearson DL, Bast RC Jr.

Am J Obstet Gynecol. 1991 Mar;164(3):745-50.

PMID:
2003535

Supplemental Content

Loading ...
Support Center